Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Protoplasts of Streptomyces hygroscopicus 155 producing nigericin, a polyether antibiotic, were prepared. Conditions for protoplasting and optimal concentrations of
lysozyme
and glycine, and the age of mycelium were studied. With the method of the experiment design, concentrations of four components: CaCl2, MgCl2, KH2PO4 and
TES
buffer in the regeneration medium were determined. The levels of CaCl2 and
TES
buffer proved to be the most important parameters.
...
PMID:[Preparation and regeneration of protoplasts of the strain Streptomyces hygroscopicus 155]. 130 22
To explore the mechanism of
lysozyme
stabilization in buffer system, we have investigated the interactions between
lysozyme
and the biological buffers (TRIS, TAPS, and
TES
) using spectroscopic techniques, including ultraviolet-visible (UV-Vis), fluorescence, thermal fluorescence, dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR) and circular dichroism (CD) spectroscopy. From the series of spectroscopic studies, it is found that the native structure of the protein remains intact in the different concentrations (0.05, 0.1, 0.25, 0.5, and 1.0M) of the biological buffer aqueous solutions at pH7.0. Moreover, all these three investigated buffers are able to protect
lysozyme
against thermal denaturation, particularly in high concentration (1.0M) of the buffer aqueous solutions.
...
PMID:The effects of biological buffers TRIS, TAPS, TES on the stability of lysozyme. 2942 67